Lifecore Biomedical Executive Compensation Details
Ticker: LFCR · Form: DEF 14A · Filed: Jul 19, 2024 · CIK: 1005286
| Field | Detail |
|---|---|
| Company | Lifecore Biomedical, Inc. \De\ (LFCR) |
| Form Type | DEF 14A |
| Filed Date | Jul 19, 2024 |
| Risk Level | low |
| Pages | 16 |
| Reading Time | 20 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-compensation, proxy-statement, equity-awards
TL;DR
Lifecore Biomedical DEF 14A out: Executive pay details for FY23, including equity awards for Bolles & Hall.
AI Summary
Lifecore Biomedical, Inc. filed a DEF 14A on July 19, 2024, detailing executive compensation for the fiscal year ending May 28, 2023. The filing includes information on equity awards granted to individuals such as Albert Bolles and James G. Hall, with reported values for grants made in the current and prior years, both vested and unvested.
Why It Matters
This filing provides transparency into how Lifecore Biomedical compensates its top executives, which can influence investor decisions and perceptions of company management.
Risk Assessment
Risk Level: low — This is a routine DEF 14A filing detailing executive compensation and does not appear to contain significant new risks.
Key Numbers
- 2023-05-28 — Fiscal Year End (Reporting period for executive compensation)
- 20240719 — Filing Date (Date the DEF 14A was submitted)
Key Players & Entities
- Lifecore Biomedical, Inc. (company) — Filer
- Albert Bolles (person) — Executive
- James G. Hall (person) — Executive
- 2023-05-28 (date) — Fiscal Year End
- 20240719 (date) — Filing Date
FAQ
What was the total compensation for Albert Bolles in the fiscal year ending May 28, 2023?
The filing details equity awards granted to Albert Bolles, including reported values for grants made in the current and prior years, both vested and unvested, but does not explicitly state a single total compensation figure in the provided snippet.
What is the primary purpose of a DEF 14A filing?
A DEF 14A filing, also known as a Definitive Proxy Statement, is filed with the SEC when a company is soliciting proxies from shareholders for its annual meeting.
Who is listed as a member in relation to equity awards?
Albert Bolles and James G. Hall are listed as members in relation to equity awards.
What is Lifecore Biomedical's Standard Industrial Classification (SIC) code?
Lifecore Biomedical's SIC code is 2834, which corresponds to Pharmaceutical Preparations.
When was Lifecore Biomedical formerly known as Landec Corp?
Lifecore Biomedical was formerly known as Landec Corp, with a date of name change on 19951222.
Filing Stats: 4,907 words · 20 min read · ~16 pages · Grade level 12.5 · Accepted 2024-07-19 16:05:21
Key Financial Figures
- $0.001 — f the Company's common stock, par value $0.001 per share ("Common Stock"), and holders
Filing Documents
- lndc-20240719.htm (DEF 14A) — 1124KB
- lndc-20240719_g1.jpg (GRAPHIC) — 19KB
- lndc-20240719_g2.gif (GRAPHIC) — 563KB
- lndc-20240719_g3.gif (GRAPHIC) — 551KB
- lndc-20240719_g4.gif (GRAPHIC) — 605KB
- lndc-20240719_g5.jpg (GRAPHIC) — 564KB
- lndc-20240719_g6.jpg (GRAPHIC) — 251KB
- lndc-20240719_g7.jpg (GRAPHIC) — 530KB
- lndc-20240719_g8.jpg (GRAPHIC) — 251KB
- 0001005286-24-000090.txt ( ) — 10366KB
- lndc-20240719.xsd (EX-101.SCH) — 4KB
- lndc-20240719_def.xml (EX-101.DEF) — 5KB
- lndc-20240719_lab.xml (EX-101.LAB) — 7KB
- lndc-20240719_pre.xml (EX-101.PRE) — 4KB
- lndc-20240719_htm.xml (XML) — 143KB
EXECUTIVE COMPENSATION AND RELATED INFORMATION 49
EXECUTIVE COMPENSATION AND RELATED INFORMATION 49 CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS 57 DELINQUENT SECTION 16(a) REPORTS 59 CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS 59 OTHER MATTERS 59 APPENDIX A: NASDAQ BOARD DIVERSITY DISCLOSURE 60 APPENDIX B: PROPOSED AMENDMENT TO CERTIFICATE OF INCORPORATION 61 APPENDIX C: LIFECORE BIOMEDICAL, INC. 2019 STOCK INCENTIVE PLAN 62 APPENDIX D: PROPOSED AMENDMENT TO THE CERTIFICATE OF INCORPORATION 75 The Company is providing you with this proxy statement relating to its 2023 annual meeting of stockholders (the "Proxy Statement"). The Company expects to commence mailing of its proxy materials to stockholders on or about July 19, 2024. References to the "Company," "Lifecore," "we," or "our" in this Proxy Statement refer to Lifecore Biomedical, Inc. and, as applicable, its consolidated subsidiaries. The Company's website and the information contained or linked therein are not part of or incorporated by reference into this Proxy Statement, regardless of any reference to the website in the Proxy Statement. 2023 ANNUAL MEETING OF STOCKHOLDERS TO BE HELD ON AUGUST 15, 2024 This Proxy Statement and proxy card are furnished in connection with the solicitation of proxies by the Board of Directors (the "Board") of the Company for use at the 2023 annual meeting of stockholders of the Company (the "Annual Meeting"). The Annual Meeting will be held virtually via live webcast on August 15, 2024 at 10:30 a.m. (Central Time). The Annual Meeting can be accessed by visiting www.virtualshareholdermeeting.com/LFCR2023, where you will be able to listen to the meeting live and vote online for the proposals described in this Proxy Statement. You will not be able to attend the Annual Meeting physically in person. The Board has fixed the close of business on June 21, 2024 as the record date for the Annual Meeting (the "Record Date"). Stockholders of record as of the Record Date are entitled to notice of and to vo